ArticleMolecular and cellular pediatrics2026
Real-world impact of nirsevimab on RSV hospitalizations in children under 2 years of age: retrospective monocentric study in a large German tertiary pedatric center.
Article in Molecular and cellular pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRespiratory syncytial virus (RSV) infection is a leading cause of hospitalization among infants and young children. Broad immunization with the monoclonal antibody nirsevimab represents a promising preventive strategy. However, real-world data on its impact at the population level remain limited, particularly in routine clinical settings.
methodsThis retrospective single-center study evaluated a cohort of 261 children under two years of age hospitalized with RSV across three seasons (2018-2019, 2023-2024, 2024-2025) at a Berlin tertiary care hospital.
resultsWe analyzed admissions and clinical courses of RSV-associated hospitalizations in children < 2 years of age at a large tertiary care center in Germany between 2018 and 2025. Following the nationwide introduction of nirsevimab in 2024, the number of RSV-related hospitalizations in our center decreased by 51% compared to the previous season. During the 2024/2025 season 90.2% of hospitalized patients had not received nirsevimab immunization.
conclusionThe introduction of nirsevimab was associated with a substantial reduction in RSV-related hospitalizations in infants and young children in a real-world clinical setting. These findings support a beneficial role of passive immunization with nirsevimab and highlight its potential to reduce RSV-related disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.